Tasigna, a popular cancer drug, has reportedly been linked to a form of cardiovascular disease, atherosclerosis, that causes the buildup of plaque in arteries. The buildup of plaque, which allows arteries to harden and thicken leads to an astounding number of other cardiovascular complications and events.

As a result, a number of cancer patients have filed Tasigna atherosclerosis lawsuits over adverse side effects and fatal health consequences. Health risks, including Tasgina atherosclerosis, are allegedly still not being adequately warned of by the company’s manufacturer, Novartis. Patients and physicians, however, were warned of these consequences in Canada, according to lawsuits in the United States.

Overview: Tasigna Atherosclerosis

Tasigna was approved by the U.S. Food and Drug Administration (FDA) in 2007. The drug was developed to treat chronic myeloid leukemia (CML). As part of a family known as tyrosine kinase inhibitors (TKI), it targets an enzyme (BCR-ABL) responsible for the growth of cancer.

However, there are health risks and complications reportedly associated with the medication. While the drug attempts to treat cancer patients, it may also endanger the very patients that it treats. The medication is allegedly believed to causes atherosclerosis.

Atherosclerosis is a condition that decreases blood flow as the walls of the arteries narrow from white blood cell buildup and fibrofatty plaque. According to Tasgina atherosclerosis lawsuits, an astounding number of patients are complaining of cardiovascular complications and adverse side effects. Some of these cardiovascular injuries include strokes, heart attacks, and sudden death.

Drug maker Novartis is accused of failing to warn Americans of the serious adverse complications and injuries associated with Tasigna, including Tasgina atherosclerosis. They have also not settled any civil lawsuits.

In 2015, the company settled a $390 million civil fraud lawsuit with the U.S. Department of Justice (DOJ). According to the DOJ, “Novartis incentivized and pressured the pharmacies to emphasize benefits to patients while understating the drug’s serious, potentially life-threatening side effects.” The company was accused of illegal marketing practices which included kickbacks for through drug rebates and paid patient referrals.

The first wrongful death lawsuit was filed against Novartis in 2016. According to the plaintiff, Dainis L. was prescribed and had taken Tasigna for more than one year. However, he allegedly developed “severe, accelerated, and irreversible” adverse side effects, including Tasigna atherosclerosis. He allegedly suffered from a complete blockage of his femoral arteries. As a result, there was substantial irregular blood flow to his legs.

Other side effects he suffered allegedly included a 40-60 percent coronary artery narrowing and 70 percent cerebral artery narrowing. He later died from a stroke that damaged his cerebral arteries in March 2014.

Accusations filed against the company claim they knew about the drug’s side effects and complications. However, the company never disclosed them to patients or the U.S. market.

Although it is impossible to reverse Tasigna atherosclerosis side effects and complications, Novartis allegedly has yet to warn Americans of the serious injuries associated with the drug. The FDA has also failed to step in and protect patients. If you or a loved one have suffered from Tasigna atherosclerosis side effects, it’s essential to take immediate action and hold Novartis accountable for their actions.